Aripiprazole Oral Acceptability Trial

Phase 3

Completed

• Conditions: Schizophrenia
• Interventions: Drug: Aripiprazole

• Registration Number: NCT00101569
• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Brief Summary

The purpose of this trial is to study liquid aripiprazole in patients with stable schizophrenia.

Detailed Description

Not available

Study Timeline

• Study Start: 2004-03
• Study First Submitted: 2005-01-12
• Study First Submitted QC: 2005-01-12
• Study First Posted: 2005-01-13
• Primary Completion: 2005-03
• Study Completion: 2005-03
• Status Verified: 2008-07
• Last Update Submitted: 2013-11-07
• Last Update Posted: 2013-11-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 59

Inclusion Criteria

• Stable patients currently receiving aripiprazole or other antipsychotic medications.

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
A1	Aripiprazole	-
A2	Aripiprazole	-

Primary Outcome Measures

Name	Time	Method
acceptability

Trial Locations

Locations (1)

Local Institution; 🇺🇸 Falls Church, Virginia, United States